Protection of Normal Tissues from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine (WR-2721): Preclinical Aspects

This publication has 30 references indexed in Scilit:

• Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
  European Journal Of Cancer, 1994
• Phase I study of WR-2721 and carboplatin
  European Journal Of Cancer, 1993
• Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice
  European Journal Of Cancer, 1992
• The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation
  Carcinogenesis: Integrative Cancer Research, 1992
• Antimutagenic Effects of Radioprotector WR-2721 Against Fission-spectrum Neutrons and⁶⁰Co γ-rays in Mice
  International Journal of Radiation Biology, 1992
• In VivoProtection by the Aminothiol WR-2721 against Neutron-induced Carcinogenesis
  International Journal of Radiation Biology, 1992
• New Protective Agents for Bone Marrow in Cancer Therapy
  Cancer Investigation, 1991
• Radiation Protectors: the Unexpected Benefits
  Drug Metabolism Reviews, 1989
• Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
  Cancer, 1988
• Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio
  Pharmacology & Therapeutics, 1988